Table 1

Demographic and clinical baseline characteristics of all randomized patients with non-squamous NSCLC (maintenance phasea)
Characteristic Pemetrexed/BSC (n = 28) BSC alone (n = 27)
Median age (range), years 61 (22-75) 59 (48-83)
Males, n (%) 20 (71.4) 17 (63.0)
Race, n (%)
Caucasian 26 (92.9) 26 (96.3)
African 2 (7.1) 1 (3.7)
ECOG PS, n (%)
0 8 (28.6) 6 (22.2)
1 20 (71.4) 21 (77.8)
Prior therapy, n (%)
Radiotherapy 2 (7.1) 1 (3.7)
Curative surgery 0 (0.0) 2 (7.4)
Disease stageb, n (%)
IIIB 9 (32.1) 10 (37.0)
IV 19 (67.9) 17 (63.0)
Histologic subtype, n (%)
Adenocarcinoma 19 (67.9) 21 (77.8)
Large cell 8 (28.6) 5 (18.5)
Mixed cell 1 (3.6) 1 (3.7)
Smoking status, n (%)
Current smoker 8 (28.6) 6 (22.2)
Former smoker 8 (28.6) 11 (40.7)
Never smoker 12 (42.9) 10 (37.0)
Best tumor response, n (%)c
Complete response (CR) 0 (0.0) 1 (3.7)
Partial response (PR) 10 (35.7) 11 (40.7)
Stable disease (SD) 17 (60.7) 13 (48.1
Unknown 1 (3.6) 2 (7.4)

Abbreviations: BSC = best supportive care; ECOG PS = Eastern Cooperative Oncology Group Performance Status.

Note: The sum of percentages for some characteristics do not add up to 100% due to rounding.

aMaintenance phase was defined as visit 5 to the visit prior to the post-treatment phase (i.e. the data of progression or the start of a new anti-cancer therapy treatment).

bBased on TNM Classification, 6th edition.

cThe best overall tumor response during the induction therapy phase. This was used as the stratification factor for randomization to one of the maintenance phase arms.

Mubarak et al.

Mubarak et al. BMC Cancer 2012 12:423   doi:10.1186/1471-2407-12-423

Open Data